Skip to main content
OpenTrials

Clinical trial condition

Neuroectodermal Tumors

Explore clinical trials studying Neuroectodermal Tumors. Study availability and eligibility vary by location and protocol.

5,995 public trials 1,209 recruiting studies
Refine in advanced search Browse all conditions

Neuroectodermal Tumors trial results

Active, Not Recruiting

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Riley Hospital for Children Indianapolis, Indiana, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • The Hospital for Sick Children Toronto, Canada
  • Rigshospitalet Copenhagen, Denmark
View all 20 locations
View Trial Details
Active, Not Recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT03180502

Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Boca Raton Regional Hospital Boca Raton, Florida, United States
  • Miami Cancer Institute Miami, Florida, United States
  • Emory Proton Therapy Center Atlanta, Georgia, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

NCT05415072

Conditions
Eye Diseases, Eye Neoplasms, Melanoma, +15 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Columbia University Medical Center New York, United States
  • Memorial Sloane Ketterin Cancer Ctr New York, United States
  • Novartis Investigative Site Westmead, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Islet Cell, +19 more
Locations
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 673 locations
View Trial Details
Active, Not Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983

Conditions
Adnexal Diseases, Advanced or Metastatic Solid Tumors, Breast Diseases, +64 more
Locations
  • Massachusetts General Hospital - Boston Boston, Massachusetts, United States
  • John Theurer Cancer Center Hackensack, New Jersey, United States
  • Mount Sinai Tisch Cancer Center New York, United States
  • NEXT Oncology - Dallas Dallas, Texas, United States
View Trial Details

Related conditions